Patents by Inventor Shyh-Ming Yang
Shyh-Ming Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240368087Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: ApplicationFiled: February 5, 2024Publication date: November 7, 2024Inventors: David J. MALONEY, Alex Gregory WATERSON, Ganesh Rai BANTUKALLU, Kyle Ryan BRIMACOMBE, Plamen CHRISTOV, Chi V. DANG, Victor DARLEY-USMAR, Xin HU, Ajit JADHAV, Somnath JANA, Kwangho KIM, Jennifer L. KOUZNETSOVA, William J. MOORE, Bryan T. MOTT, Leonard M. NECKERS, Anton SIMEONOV, Gary Allen SULIKOWSKI, Daniel Jason URBAN, Shyh Ming YANG
-
Patent number: 11897845Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: GrantFiled: January 10, 2022Date of Patent: February 13, 2024Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
-
Patent number: 11795177Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.Type: GrantFiled: February 28, 2022Date of Patent: October 24, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Shyh Ming Yang, David J. Maloney, Natalia Martinez, Adam Yasgar, Anton Simeonov
-
Publication number: 20230079399Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde de-hydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumorsbreast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.Type: ApplicationFiled: February 28, 2022Publication date: March 16, 2023Inventors: Shyh Ming YANG, David J. MALONEY, Natalia MARTINEZ, Adam YASGAR, Anton SIMEONOV
-
Patent number: 11505559Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.Type: GrantFiled: October 30, 2018Date of Patent: November 22, 2022Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH, YALE UNIVERSITYInventors: Shyh Ming Yang, David J. Maloney, Natalia Martinez, Adam Yasgar, Anton Simeonov, Vasilis Vasiliou
-
Patent number: 11426415Abstract: The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases.Type: GrantFiled: March 6, 2018Date of Patent: August 30, 2022Assignees: Washington University, The United States of America, As Represented by the Secretary, Department of Health and Human ServicesInventors: Fumihiko Urano, Jana Mahadevan, Amy Clark, Ajit Jadhav, David Maloney, Brandon Harvey, Shyh-ming Yang, Mark Henderson
-
Publication number: 20220259200Abstract: The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.Type: ApplicationFiled: March 11, 2020Publication date: August 18, 2022Inventors: Jeffrey W. STROVEL, Makoto YOSHIOKA, David J. MALONEY, Shyh Ming YANG, Ajit JADHAV, Daniel Jason URBAN
-
Publication number: 20220220078Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: ApplicationFiled: January 10, 2022Publication date: July 14, 2022Inventors: David J. MALONEY, Alex Gregory WATERSON, Ganesh Rai BANTUKALLU, Kyle Ryan BRIMACOMBE, Plamen CHRISTOV, Chi V. DANG, Victor DARLEY-USMAR, Xin HU, Ajit JADHAV, Somnath JANA, Kwangho KIM, Jennifer L. KOUZNETSOVA, William J. MOORE, Bryan T. MOTT, Leonard M. NECKERS, Anton SIMEONOV, Gary Allen SULIKOWSKI, Daniel Jason URBAN, Shyh Ming YANG
-
Patent number: 11247971Abstract: Provided is a compound of formula (I), in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: GrantFiled: January 28, 2021Date of Patent: February 15, 2022Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE UAB RESEARCH FOUNDATION, VANDERBILT UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
-
Publication number: 20210323928Abstract: Provided is a compound of formula (I)[Formula (I) should be inserted here], in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: ApplicationFiled: January 28, 2021Publication date: October 21, 2021Inventors: David J. MALONEY, Alex Gregory WATERSON, Ganesh Rai BANTUKALLU, Kyle Ryan BRIMACOMBE, Plamen CHRISTOV, Chi V. DANG, Victor DARLEY-USMAR, Xin HU, Ajit JADHAV, Somnath JANA, Kwangho KIM, Jennifer L. KOUZNETSOVA, William J. MOORE, Bryan T. MOTT, Leonard M. NECKERS, Anton SIMEONOV, Gary Allen SULIKOWSKI, Daniel Jason URBAN, Shyh Ming YANG
-
Patent number: 11098016Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: GrantFiled: August 12, 2020Date of Patent: August 24, 2021Assignee: JANSSEN PHARMACEUTICA NVInventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Publication number: 20210179630Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumorsbreast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.Type: ApplicationFiled: October 30, 2018Publication date: June 17, 2021Inventors: Shyh Ming YANG, David J. MALONEY, Natalia MARTINEZ, Adam YASGAR, Anton SIMEONOV, Vasilis VASILIOU
-
Publication number: 20210128580Abstract: The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases.Type: ApplicationFiled: March 6, 2018Publication date: May 6, 2021Applicants: Washington University, The United States of America, As Represented by the Secretary, Department Health and Human ServiceInventors: Fumihiko Urano, Jana Mahadevan, Amy Clark, Ajit Jadhav, David Maloney, Brandon Harvey, Shyh-ming Yang, Mark Henderson
-
Patent number: 10961200Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: GrantFiled: June 28, 2019Date of Patent: March 30, 2021Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
-
Patent number: 10954228Abstract: The disclosure provides a compound of the formula (II) and pharmaceutically acceptable salts thereof. The variables, e.g. n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful for treating cancer and fibrosis. The compounds may be particularly useful for treating forms of cancer in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred. The disclosure also provides pharmaceutical compositions containing a compound of this formula and method for treating patients having cancer, fibrosis, or other conditions in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred.Type: GrantFiled: June 29, 2017Date of Patent: March 23, 2021Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE UAB RESEARCH FOUNDATION, VANDERBILT UNIVERSITY, NATIONAL INSTITUTES OF HEALTH, UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICESInventors: David J. Maloney, Alex Gregory Waterson, Ganesha Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor M. Darley-Usmar, Matthew Hall, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
-
Publication number: 20200377462Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: ApplicationFiled: August 12, 2020Publication date: December 3, 2020Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Patent number: 10774048Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: GrantFiled: January 8, 2019Date of Patent: September 15, 2020Assignee: JANSSEN PHARMACEUTICA NVInventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Publication number: 20200223836Abstract: The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.Type: ApplicationFiled: November 15, 2019Publication date: July 16, 2020Inventors: Jeffrey William Strovel, Makoto Yoshioka, David J. Maloney, Shyh Ming Yang, Ajit Jadhav, Daniel Jason Urban, JR.
-
Patent number: 10662170Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.Type: GrantFiled: October 30, 2018Date of Patent: May 26, 2020Assignee: Janssen Pharmaceutica NVInventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
-
Publication number: 20200002285Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: ApplicationFiled: June 28, 2019Publication date: January 2, 2020Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang